US6727230B1
(en)
|
1994-03-25 |
2004-04-27 |
Coley Pharmaceutical Group, Inc. |
Immune stimulation by phosphorothioate oligonucleotide analogs
|
US6239116B1
(en)
|
1994-07-15 |
2001-05-29 |
University Of Iowa Research Foundation |
Immunostimulatory nucleic acid molecules
|
US6111166A
(en)
*
|
1994-09-19 |
2000-08-29 |
Medarex, Incorporated |
Transgenic mice expressing human Fcα and β receptors
|
US6267958B1
(en)
|
1995-07-27 |
2001-07-31 |
Genentech, Inc. |
Protein formulation
|
US6685940B2
(en)
|
1995-07-27 |
2004-02-03 |
Genentech, Inc. |
Protein formulation
|
WO1997035619A1
(en)
*
|
1996-03-28 |
1997-10-02 |
Genitrix, L.L.C. |
Opsonin-enhanced cells, and methods of modulating an immune response to an antigen
|
US7371376B1
(en)
*
|
1996-10-18 |
2008-05-13 |
Genentech, Inc. |
Anti-ErbB2 antibodies
|
DE19725586C2
(de)
*
|
1997-06-17 |
1999-06-24 |
Gsf Forschungszentrum Umwelt |
Verfahren zur Herstellung von Zellpräparaten zur Immunisierung mittels heterologer intakter bispezifischer und/oder trispezifischer Antikörper
|
DE19735105A1
(de)
*
|
1997-08-13 |
1999-03-04 |
Univ Albert Ludwigs Freiburg |
Transportsystem zur Einbringung von Proteinen in Zielzellen mit Hilfe eines Fusionsproteins, Nucleinsäurekonstrukte kodierend für die Komponenten des Transportsystems und Arzneimittel, die Komponenten des Transportsystems umfassen
|
EP1044263A2
(en)
|
1997-12-02 |
2000-10-18 |
Medarex, Inc. |
CELLS EXPRESSING ANTI-Fc RECEPTOR BINDING COMPONENTS
|
ZA9811162B
(en)
|
1997-12-12 |
2000-06-07 |
Genentech Inc |
Treatment with anti-ERBB2 antibodies.
|
US6962702B2
(en)
*
|
1998-06-22 |
2005-11-08 |
Immunomedics Inc. |
Production and use of novel peptide-based agents for use with bi-specific antibodies
|
US7405320B2
(en)
|
1998-06-22 |
2008-07-29 |
Immunomedics, Inc. |
Therapeutic and diagnostic conjugates for use with multispecific antibodies
|
US7138103B2
(en)
*
|
1998-06-22 |
2006-11-21 |
Immunomedics, Inc. |
Use of bi-specific antibodies for pre-targeting diagnosis and therapy
|
US7833528B2
(en)
*
|
1998-06-22 |
2010-11-16 |
Immunomedics, Inc. |
Use of multispecific, non-covalent complexes for targeted delivery of therapeutics
|
US7387772B1
(en)
|
1999-06-22 |
2008-06-17 |
Immunimedics, Inc. |
Chimeric, human and humanized anti-CSAP monoclonal antibodies
|
US20030022854A1
(en)
|
1998-06-25 |
2003-01-30 |
Dow Steven W. |
Vaccines using nucleic acid-lipid complexes
|
WO2000020027A2
(en)
*
|
1998-10-05 |
2000-04-13 |
M & E Biotech A/S |
Methods for therapeutic vaccination
|
US20040013667A1
(en)
*
|
1999-06-25 |
2004-01-22 |
Genentech, Inc. |
Treatment with anti-ErbB2 antibodies
|
US7041292B1
(en)
|
1999-06-25 |
2006-05-09 |
Genentech, Inc. |
Treating prostate cancer with anti-ErbB2 antibodies
|
US6949245B1
(en)
*
|
1999-06-25 |
2005-09-27 |
Genentech, Inc. |
Humanized anti-ErbB2 antibodies and treatment with anti-ErbB2 antibodies
|
US20030086924A1
(en)
*
|
1999-06-25 |
2003-05-08 |
Genentech, Inc. |
Treatment with anti-ErbB2 antibodies
|
PT1189634E
(pt)
*
|
1999-06-25 |
2007-06-06 |
Genentech Inc |
Tratamento de cancro da próstata com anticorpos anti-erbb2.
|
KR100996759B1
(ko)
|
1999-08-24 |
2010-11-25 |
메다렉스, 인코포레이티드 |
인간 씨티엘에이-4 항체 및 그의 용도
|
PT1210115E
(pt)
|
1999-08-27 |
2009-11-12 |
Genentech Inc |
Dosagens para tratamento com anticorpos anti-erbb2
|
DE19962583A1
(de)
*
|
1999-12-23 |
2001-06-28 |
Mueller Hermelink Hans Konrad |
Antikörper gegen Plasmazellen
|
WO2001048205A2
(en)
*
|
1999-12-29 |
2001-07-05 |
Corixa Corporation |
Murine neu sequences and methods of use therefor
|
WO2001083781A2
(en)
*
|
2000-04-28 |
2001-11-08 |
Millennium Pharmaceuticals, Inc. |
14094, a novel human trypsin family member and uses thereof
|
KR20030007640A
(ko)
*
|
2000-05-19 |
2003-01-23 |
제넨테크, 인크. |
ErbB 길항제에 의한 암 치료요법에 대한 효과적인반응의 가능성을 개선시키기 위한 유전자 검출 분석
|
JP2004509978A
(ja)
*
|
2000-06-05 |
2004-04-02 |
ユニバーシティ オブ テネシー コーポレイション |
免疫抑制因子のエンドサイトーシスによる提示のための組成物及び方法
|
US8568766B2
(en)
|
2000-08-24 |
2013-10-29 |
Gattadahalli M. Anantharamaiah |
Peptides and peptide mimetics to treat pathologies associated with eye disease
|
DE10043437A1
(de)
*
|
2000-09-04 |
2002-03-28 |
Horst Lindhofer |
Verwendung von trifunktionellen bispezifischen und trispezifischen Antikörpern zur Behandlung von malignem Aszites
|
AU2002228771B2
(en)
|
2000-11-02 |
2007-10-25 |
Sloan-Kettering Institute For Cancer Research |
Small molecule compositions for binding to HSP90
|
ES2390425T3
(es)
|
2000-12-22 |
2012-11-12 |
MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. |
Uso de moléculas de orientación repulsivas (RGM) y sus moduladores
|
US7754208B2
(en)
|
2001-01-17 |
2010-07-13 |
Trubion Pharmaceuticals, Inc. |
Binding domain-immunoglobulin fusion proteins
|
US7265208B2
(en)
|
2001-05-01 |
2007-09-04 |
The Regents Of The University Of California |
Fusion molecules and treatment of IgE-mediated allergic diseases
|
DK2163256T3
(en)
|
2001-05-11 |
2015-12-07 |
Ludwig Inst For Cancer Res Ltd |
Specific binding proteins and use thereof
|
US20100056762A1
(en)
|
2001-05-11 |
2010-03-04 |
Old Lloyd J |
Specific binding proteins and uses thereof
|
JP2004529188A
(ja)
|
2001-05-23 |
2004-09-24 |
スローン − ケッタリング インスティチュート フォー キャンサー リサーチ |
上昇に関連した癌の治療法
|
US6818787B2
(en)
*
|
2001-06-11 |
2004-11-16 |
Xenoport, Inc. |
Prodrugs of GABA analogs, compositions and uses thereof
|
JP4303105B2
(ja)
*
|
2001-06-28 |
2009-07-29 |
ドマンティス リミテッド |
二重特異性リガンドとその利用
|
US20050271663A1
(en)
*
|
2001-06-28 |
2005-12-08 |
Domantis Limited |
Compositions and methods for treating inflammatory disorders
|
GB0124670D0
(en)
*
|
2001-10-15 |
2001-12-05 |
Hewlett Packard Co |
Method and apparatus for encrypting data
|
GB0124686D0
(en)
|
2001-10-15 |
2001-12-05 |
Hewlett Packard Co |
A scheme for splitting trusted authorities based on the shamir's secret sharing
|
GB0124681D0
(en)
*
|
2001-10-15 |
2001-12-05 |
Hewlett Packard Co |
Method and apparatus for encrypting data
|
US7491690B2
(en)
*
|
2001-11-14 |
2009-02-17 |
Northwestern University |
Self-assembly and mineralization of peptide-amphiphile nanofibers
|
EP1527341B1
(en)
|
2001-11-20 |
2009-06-17 |
Duke University |
Interfacial biomaterials
|
KR20100094569A
(ko)
|
2002-02-06 |
2010-08-26 |
비코르 테크놀로지스 인코포레이티드 |
경색방지 분자
|
AU2003216436A1
(en)
|
2002-02-08 |
2003-09-02 |
Life Technologies Corporation |
Compositions and methods for restoring immune responsiveness in patients with immunological defects
|
AU2003215280A1
(en)
*
|
2002-02-15 |
2003-09-09 |
Northwestern University |
Self-assembly of peptide-amphiphile nanofibers under physiological conditions
|
US7053188B2
(en)
*
|
2002-02-22 |
2006-05-30 |
Purdue Research Foundation |
Monoclonal antibodies specific for neoplasia-specific NADH:disulfide reductase
|
CA2485120C
(en)
|
2002-05-06 |
2013-02-19 |
The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services |
Identification of novel broadly cross-reactive hiv-1 neutralizing human monoclonal antibodies
|
US9321832B2
(en)
*
|
2002-06-28 |
2016-04-26 |
Domantis Limited |
Ligand
|
SI1517921T1
(sl)
*
|
2002-06-28 |
2006-10-31 |
Domantis Ltd |
Dvojno-specificni ligandi z zvisano serumsko razpolovno dobo
|
US7696320B2
(en)
|
2004-08-24 |
2010-04-13 |
Domantis Limited |
Ligands that have binding specificity for VEGF and/or EGFR and methods of use therefor
|
CA2495478A1
(en)
|
2002-08-05 |
2004-02-12 |
University Of Rochester |
Protein transducing domain/deaminase chimeric proteins, related compounds, and uses thereof
|
US8530627B2
(en)
*
|
2002-08-14 |
2013-09-10 |
Macrogenics, Inc. |
FcγRIIB specific antibodies and methods of use thereof
|
US8946387B2
(en)
*
|
2002-08-14 |
2015-02-03 |
Macrogenics, Inc. |
FcγRIIB specific antibodies and methods of use thereof
|
US8044180B2
(en)
*
|
2002-08-14 |
2011-10-25 |
Macrogenics, Inc. |
FcγRIIB specific antibodies and methods of use thereof
|
JP4459810B2
(ja)
*
|
2002-08-14 |
2010-04-28 |
マクロジェニクス,インコーポレーテッド |
FcγRIIB特異的抗体とその利用法
|
US8968730B2
(en)
*
|
2002-08-14 |
2015-03-03 |
Macrogenics Inc. |
FcγRIIB specific antibodies and methods of use thereof
|
US8193318B2
(en)
*
|
2002-08-14 |
2012-06-05 |
Macrogenics, Inc. |
FcγRIIB specific antibodies and methods of use thereof
|
US8187593B2
(en)
*
|
2002-08-14 |
2012-05-29 |
Macrogenics, Inc. |
FcγRIIB specific antibodies and methods of use thereof
|
US7534761B1
(en)
|
2002-08-21 |
2009-05-19 |
North Western University |
Charged peptide-amphiphile solutions and self-assembled peptide nanofiber networks formed therefrom
|
JP2006513702A
(ja)
*
|
2002-09-09 |
2006-04-27 |
ヌラ インコーポレーティッド |
Gタンパク質共役受容体およびその使用
|
US20080260744A1
(en)
|
2002-09-09 |
2008-10-23 |
Omeros Corporation |
G protein coupled receptors and uses thereof
|
US7148332B2
(en)
|
2002-09-11 |
2006-12-12 |
Spring Bioscience |
High affinity monoclonal antibody for recognizing the estrogen receptor (ER) and method for creating the antibody
|
CA2505326A1
(en)
*
|
2002-11-08 |
2004-05-21 |
Ablynx N.V. |
Camelidae antibodies against immunoglobulin e and use thereof for the treatment of allergic disorders
|
EP1558646A2
(en)
*
|
2002-11-08 |
2005-08-03 |
Ablynx N.V. |
Single domain antibodies directed against interferon- gamma and uses thereof
|
CN102584997A
(zh)
*
|
2002-11-08 |
2012-07-18 |
埃博灵克斯股份有限公司 |
针对肿瘤坏死因子-α的单结构域抗体及其用途
|
US9320792B2
(en)
|
2002-11-08 |
2016-04-26 |
Ablynx N.V. |
Pulmonary administration of immunoglobulin single variable domains and constructs thereof
|
US20100003253A1
(en)
*
|
2002-11-08 |
2010-01-07 |
Ablynx N.V. |
Single domain antibodies directed against epidermal growth factor receptor and uses therefor
|
US20060034845A1
(en)
*
|
2002-11-08 |
2006-02-16 |
Karen Silence |
Single domain antibodies directed against tumor necrosis factor alpha and uses therefor
|
US7554021B2
(en)
|
2002-11-12 |
2009-06-30 |
Northwestern University |
Composition and method for self-assembly and mineralization of peptide amphiphiles
|
WO2004046167A2
(en)
*
|
2002-11-14 |
2004-06-03 |
Northwestern University |
Synthesis and self-assembly of abc triblock bola peptide
|
EP1572972A4
(en)
*
|
2002-11-21 |
2007-11-21 |
Genentech Inc |
THERAPY OF NON-MALIGNER DISEASES OR DISORDER WITH ANTI-ERBB2 ANTIBODIES
|
US7597936B2
(en)
*
|
2002-11-26 |
2009-10-06 |
University Of Utah Research Foundation |
Method of producing a pigmented composite microporous material
|
AU2003293015A1
(en)
*
|
2002-11-26 |
2004-06-18 |
University Of Utah Research Foundation |
Microporous materials, methods, and articles for localizing and quantifying analytes
|
JP2006512927A
(ja)
|
2002-12-11 |
2006-04-20 |
コーリー ファーマシューティカル グループ,インコーポレイテッド |
5’cpg核酸およびその使用方法
|
AU2003290330A1
(en)
*
|
2002-12-27 |
2004-07-22 |
Domantis Limited |
Dual specific single domain antibodies specific for a ligand and for the receptor of the ligand
|
JP2006524039A
(ja)
*
|
2003-01-09 |
2006-10-26 |
マクロジェニクス,インコーポレーテッド |
変異型Fc領域を含む抗体の同定および作製ならびにその利用法
|
US7960512B2
(en)
|
2003-01-09 |
2011-06-14 |
Macrogenics, Inc. |
Identification and engineering of antibodies with variant Fc regions and methods of using same
|
WO2005011619A2
(en)
*
|
2003-01-31 |
2005-02-10 |
Five Prime Therapeutics, Inc. |
Lung-expressed polypeptides
|
EP1606065A4
(en)
|
2003-02-11 |
2010-09-29 |
Univ Northwestern |
METHOD AND MATERIALS FOR NANOCRYSTALLINE SURFACE COATINGS AND ATTACHMENT OF AMPHIPHILENE PEPTIDE NANO FIBERS THEREOF
|
WO2005018669A1
(en)
*
|
2003-08-18 |
2005-03-03 |
Macrogenics, Inc. |
Fcϝriib-specific antibodies and methods of use thereof
|
ATE541580T1
(de)
|
2003-12-05 |
2012-02-15 |
Univ Northwestern |
Selbst anordnende peptid-amphiphile und relevante verfahren für die abgabe von wachstumsfaktor
|
EP1696944A4
(en)
|
2003-12-05 |
2008-11-05 |
Univ Northwestern |
BRANCHED PEPTIDE AMPHIPHILES, RELATED EPITOPES COMPOUNDS AND SELF-ASSOCIATED STRUCTURES THEREOF
|
JP2007518422A
(ja)
|
2004-01-21 |
2007-07-12 |
ユニバーシティ・オブ・ユタ・リサーチ・ファウンデーション |
変異体ナトリウムチャンネルNaν1.7およびそれに関連する方法
|
EP1747237A4
(en)
*
|
2004-04-16 |
2008-05-21 |
Macrogenics Inc |
SPECIFIC GAMMA FC ANTIBODIES AND METHODS OF USING THE SAME
|
JP2007536932A
(ja)
|
2004-05-10 |
2007-12-20 |
マクロジェニクス,インコーポレーテッド |
ヒト化FcγRIIB特異的抗体とその利用法
|
US20080069867A1
(en)
*
|
2004-09-16 |
2008-03-20 |
Mitsubishi Pharma Corporation |
Diagnostic and/or Remedy for Ovarian Cancer
|
US7632497B2
(en)
|
2004-11-10 |
2009-12-15 |
Macrogenics, Inc. |
Engineering Fc Antibody regions to confer effector function
|
US7449184B2
(en)
|
2005-01-21 |
2008-11-11 |
Genentech, Inc. |
Fixed dosing of HER antibodies
|
WO2006084030A2
(en)
|
2005-02-01 |
2006-08-10 |
Sloan-Kettering Institute For Cancer Research |
Small-molecule hsp90 inhibitors
|
US9403828B2
(en)
|
2005-02-01 |
2016-08-02 |
Sloan-Kettering Institute For Cancer Research |
Small-molecule Hsp90 inhibitors
|
EP1846558A2
(en)
*
|
2005-02-09 |
2007-10-24 |
Genentech, Inc. |
Inhibiting her2 shedding with matrix metalloprotease antagonists
|
HUE025945T2
(en)
|
2005-02-15 |
2016-07-28 |
Univ Duke |
Anti-CD19 antibodies and their applications in oncology
|
US20060263357A1
(en)
|
2005-05-05 |
2006-11-23 |
Tedder Thomas F |
Anti-CD19 antibody therapy for autoimmune disease
|
RU2404806C2
(ru)
*
|
2005-02-23 |
2010-11-27 |
Дженентек, Инк. |
Продление времени до прогрессирования заболевания или продолжительности жизни у онкологических больных с применением ингибиторов димеризации her
|
EP1853917A4
(en)
*
|
2005-03-04 |
2008-09-10 |
Univ Northwestern |
ANGIOGENIC HEPARIN BINDING EPITOPES, PEPTIDE AMPHIPHILES, SELF-ASSEMBLED COMPOSITIONS AND METHODS OF USE THEREOF
|
US20060204505A1
(en)
*
|
2005-03-08 |
2006-09-14 |
Sliwkowski Mark X |
Methods for identifying tumors responsive to treatment with HER dimerization inhibitors (HDIs)
|
EP2161336B2
(en)
|
2005-05-09 |
2017-03-29 |
ONO Pharmaceutical Co., Ltd. |
Human monoclonal antibodies to programmed death 1(PD-1) and methods for treating cancer using anti-PD-1 antibodies alone or in combination with other immunotherapeutics
|
JP2006316040A
(ja)
|
2005-05-13 |
2006-11-24 |
Genentech Inc |
Herceptin(登録商標)補助療法
|
EP2371843B1
(en)
|
2005-05-19 |
2014-09-17 |
THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by the Secretary, Department of Health and Human Services |
Functional epitopes of streptococcus pneumoniae psaA antigen and uses thereof
|
PT2314623E
(pt)
|
2005-06-21 |
2012-10-02 |
Xoma Technology Ltd |
Anticorpos de ligação a il-1β e os seus fragmentos
|
AU2006265108C1
(en)
|
2005-07-01 |
2013-01-17 |
E. R. Squibb & Sons, L.L.C. |
Human monoclonal antibodies to programmed death ligand 1 (PD-L1)
|
PL1912675T3
(pl)
|
2005-07-25 |
2014-10-31 |
Emergent Product Dev Seattle |
Zmniejszanie liczby komórek B za pomocą cząsteczek wiążących swoistych dla antygenów CD37 i CD20
|
EP1919503B1
(en)
|
2005-08-10 |
2014-09-24 |
MacroGenics, Inc. |
Identification and engineering of antibodies with variant fc regions and methods of using same
|
EP1928905B1
(de)
|
2005-09-30 |
2015-04-15 |
AbbVie Deutschland GmbH & Co KG |
Bindungsdomänen von proteinen der repulsive guidance molecule (rgm) proteinfamilie und funktionale fragmente davon sowie deren verwendung
|
AU2006321364B2
(en)
*
|
2005-12-01 |
2011-11-10 |
Domantis Limited |
Noncompetitive domain antibody formats that bind Interleukin 1 Receptor type 1
|
EP1968633B2
(en)
*
|
2006-01-04 |
2017-11-01 |
Institut National de la Santé et de la Recherche Medicale |
Combination therapy using anti-egfr and anti-her2 antibodies
|
US8470965B2
(en)
*
|
2006-03-01 |
2013-06-25 |
University Of Utah Research Foundation |
Methods and compositions related to cyclic peptide synthesis
|
WO2007103739A2
(en)
*
|
2006-03-01 |
2007-09-13 |
The University Of Utah Research Foundation |
Methods and compositions related to cyclic peptide synthesis
|
EP1999148B8
(en)
|
2006-03-06 |
2014-03-05 |
Medlmmune, LLC |
Humanized anti-cd22 antibodies and their use in treatment of oncology, transplantation and autoimmune disease
|
SG170110A1
(en)
*
|
2006-03-10 |
2011-04-29 |
Macrogenics Inc |
Identification and engineering of antibodies with variant heavy chains and methods of using same
|
EP2010226B1
(en)
*
|
2006-04-07 |
2014-01-15 |
The Research Foundation of State University of New York |
Transcobalamin receptor polypeptides, nucleic acids, and modulators thereof, and related methods of use in modulating cell growth and treating cancer and cobalamin deficiency
|
US9044461B2
(en)
|
2006-04-07 |
2015-06-02 |
The Research Foundation Of State University Of New York |
Transcobalamin receptor polypeptides, nucleic acids, and modulators thereof, and related methods of use in modulating cell growth and treating cancer and cobalamin deficiency
|
US7786270B2
(en)
*
|
2006-05-26 |
2010-08-31 |
Macrogenics, Inc. |
Humanized FcγRIIB-specific antibodies and methods of use thereof
|
NZ596865A
(en)
|
2006-06-12 |
2013-07-26 |
Emergent Product Dev Seattle |
Single-chain multivalent binding proteins with effector function
|
WO2008002933A2
(en)
*
|
2006-06-26 |
2008-01-03 |
Macrogenics, Inc. |
Combination of fcgammariib antibodies and cd20-specific antibodies and methods of use thereof
|
JP5764290B2
(ja)
*
|
2006-06-26 |
2015-08-19 |
マクロジェニクス,インコーポレーテッド |
FcγRIIB特異的抗体およびその使用法
|
KR101456728B1
(ko)
|
2006-09-08 |
2014-10-31 |
메디뮨 엘엘씨 |
인간화 항-cd19 항체, 및 이것의 종양학, 이식 및 자가면역 질환의 치료에서의 용도
|
US20080112961A1
(en)
*
|
2006-10-09 |
2008-05-15 |
Macrogenics, Inc. |
Identification and Engineering of Antibodies with Variant Fc Regions and Methods of Using Same
|
WO2008136852A2
(en)
|
2006-11-01 |
2008-11-13 |
University Of Rochester |
Methods and compositions related to the structure and function of apobec3g
|
US7492312B2
(en)
*
|
2006-11-14 |
2009-02-17 |
Fam Adly T |
Multiplicative mismatched filters for optimum range sidelobe suppression in barker code reception
|
JP2010509920A
(ja)
|
2006-11-15 |
2010-04-02 |
メダレックス インコーポレーティッド |
Btlaに対するヒトモノクローナル抗体および使用方法
|
WO2008140603A2
(en)
|
2006-12-08 |
2008-11-20 |
Macrogenics, Inc. |
METHODS FOR THE TREATMENT OF DISEASE USING IMMUNOGLOBULINS HAVING FC REGIONS WITH ALTERED AFFINITIES FOR FCγR ACTIVATING AND FCγR INHIBITING
|
US7695718B2
(en)
|
2006-12-20 |
2010-04-13 |
Xoma Technology Ltd. |
Methods for the treatment of IL-1β related diseases
|
WO2008085794A2
(en)
*
|
2007-01-03 |
2008-07-17 |
Burnham Institute For Medical Research |
Methods and compositions related to clot binding compounds
|
MX2009007987A
(es)
|
2007-01-25 |
2010-03-01 |
Dana Farber Cancer Inst Inc |
Uso de anticuerpos anti-egfr en el tratamiento de enfermedad mediada por egfr mutante.
|
CL2008000614A1
(es)
|
2007-03-02 |
2008-09-05 |
Genentech Inc F Hoffmann La Ro |
Metodo para tratar un paciente con un tipo de cancer que expresa el receptor her3 a un nivel bajo mediante la administracion de un inhibidor de la dimerizacion de her.
|
CN101688229B
(zh)
|
2007-03-15 |
2013-06-12 |
路德维格癌症研究所 |
包含egfr抗体和src抑制剂的组合物及其在制备用于治疗哺乳动物癌症的药物中的用途
|
US8076295B2
(en)
*
|
2007-04-17 |
2011-12-13 |
Nanotope, Inc. |
Peptide amphiphiles having improved solubility and methods of using same
|
BRPI0811466A2
(pt)
|
2007-05-07 |
2014-10-14 |
Medimmune Llc |
Anticorpo anti-icos isolado, ácido nucleico, vetor, célula isolada, métodos para produzir um anticorpo, para tratar uma doença ou distúrbio, para tratar ou prevenir a rejeição em um paciente de transplante humano, para tratar uma malignidade de célula t em um ser humano, para esgotar células t que expressam icos em um paciente humano, para romper a arquitetura do centro germinal em um órgão linfóide secundário de um primata, para esgotar células b centrais germinais de órgão linfóide secundário de um primata, e para esgotar células b comutadas em classes circulantes em um primata, e, composição farmacêutica.
|
PL2068927T3
(pl)
|
2007-05-14 |
2016-06-30 |
Medimmune Llc |
Sposoby redukcji poziomów eozynofilii
|
MX2009012676A
(es)
|
2007-05-23 |
2010-02-12 |
Uab Research Foundation |
Neuraminidasa neumococica no toxica y sus usos.
|
US8877186B2
(en)
|
2007-06-06 |
2014-11-04 |
Domantis Limited |
Polypeptides, antibody variable domains and antagonists
|
US9551033B2
(en)
*
|
2007-06-08 |
2017-01-24 |
Genentech, Inc. |
Gene expression markers of tumor resistance to HER2 inhibitor treatment
|
EP2171090B1
(en)
|
2007-06-08 |
2013-04-03 |
Genentech, Inc. |
Gene expression markers of tumor resistance to her2 inhibitor treatment
|
WO2009023386A2
(en)
*
|
2007-07-06 |
2009-02-19 |
Trubion Pharmaceuticals, Inc. |
Binding peptides having a c-terminally disposed specific binding domain
|
CN108424454B
(zh)
|
2007-08-14 |
2022-05-31 |
路德维格癌症研究所有限公司 |
靶向egf受体的单克隆抗体175及其衍生物和用途
|
WO2009026496A1
(en)
*
|
2007-08-22 |
2009-02-26 |
University Of Southern California |
Grp78 and tumor angiogenesis
|
DK2682400T5
(da)
|
2007-08-28 |
2017-11-27 |
Uab Research Foundation |
Syntetiske apolipoprotein E-efterlignende polypeptider og fremgangsmåder til anvendelse
|
WO2009032702A2
(en)
|
2007-08-28 |
2009-03-12 |
Uab Research Foundation |
Synthetic apolipoprotein e mimicking polypeptides and methods of use
|
EP2268664B1
(en)
|
2007-12-03 |
2017-05-24 |
The Government of the United States of America as represented by the Secretary of the Department of Health and Human Services |
Doc1 compositions and methods for treating cancer
|
EP2851373A1
(en)
|
2007-12-20 |
2015-03-25 |
Xoma (Us) Llc |
Methods for the treatment of gout
|
CA2708871C
(en)
|
2007-12-21 |
2017-11-21 |
Medimmune Limited |
Binding members for interleukin-4 receptor alpha (il-4r.alpha.) - 173
|
US8962803B2
(en)
|
2008-02-29 |
2015-02-24 |
AbbVie Deutschland GmbH & Co. KG |
Antibodies against the RGM A protein and uses thereof
|
CN106349390B
(zh)
|
2008-04-02 |
2019-12-10 |
宏观基因有限公司 |
Bcr-复合体-特异性抗体和其使用方法
|
PT2247304T
(pt)
|
2008-04-02 |
2016-08-29 |
Macrogenics Inc |
Anticorpos especificos de her2/neu e métodos de utilização dos mesmos
|
CN102099377A
(zh)
|
2008-04-11 |
2011-06-15 |
新兴产品开发西雅图有限公司 |
Cd37免疫治疗剂及其与双功能化学治疗剂的联合
|
EP3062106B1
(en)
|
2008-04-16 |
2020-11-11 |
The Johns Hopkins University |
Method for determining androgen receptor variants in prostate cancer
|
CA2727803C
(en)
|
2008-05-13 |
2013-03-12 |
University Of Kansas |
Metal abstraction peptide (map) tag and associated methods
|
ES2675730T3
(es)
*
|
2008-06-04 |
2018-07-12 |
Macrogenics, Inc. |
Anticuerpos con unión alterada a FcRn y métodos de uso de los mismos
|
BRPI0812682A2
(pt)
|
2008-06-16 |
2010-06-22 |
Genentech Inc |
tratamento de cáncer de mama metastático
|
AR072999A1
(es)
|
2008-08-11 |
2010-10-06 |
Medarex Inc |
Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos
|
AU2008360658B2
(en)
|
2008-08-15 |
2015-02-19 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
S0X9, prostaglandin D2 and retinoic acid for treating pigmentary conditions and melanoma
|
JP5933975B2
(ja)
|
2008-11-12 |
2016-06-15 |
メディミューン,エルエルシー |
抗体製剤
|
EP2370458B1
(en)
*
|
2008-11-28 |
2014-10-15 |
Zensun (Shanghai) Science and Technology Limited |
Neuregulin peptides and their use
|
EP2370080A1
(en)
|
2008-12-02 |
2011-10-05 |
University of Utah Research Foundation |
Pde1 as a target therapeutic in heart disease
|
TW201544123A
(zh)
|
2009-03-20 |
2015-12-01 |
Genentech Inc |
抗-her抗體
|
US8450271B2
(en)
*
|
2009-04-13 |
2013-05-28 |
Northwestern University |
Peptide-based scaffolds for cartilage regeneration and methods for their use
|
US20120121586A1
(en)
|
2009-05-29 |
2012-05-17 |
Astrid Kiermaier |
Modulators for her2 signaling in her2 expressing patients with gastric cancer
|
PT2486141T
(pt)
|
2009-10-07 |
2018-05-09 |
Macrogenics Inc |
Polipéptidos contendo uma região fc que apresenta uma função efectora melhorada, devido a modificações do grau de fucosilação, e métodos para a sua utilização
|
WO2011043980A1
(en)
|
2009-10-07 |
2011-04-14 |
Sanford Burnham Medical Research Institute |
Methods and compositions related to clot-binding lipid compounds
|
CA2780069C
(en)
|
2009-12-08 |
2018-07-17 |
Abbott Gmbh & Co. Kg |
Monoclonal antibodies against the rgm a protein for use in the treatment of retinal nerve fiber layer degeneration
|
CA2784145A1
(en)
|
2009-12-18 |
2011-06-23 |
Sanford-Burnham Medical Research Institute |
Methods and compositions related to clot-binding compounds
|
KR20130009760A
(ko)
|
2010-02-10 |
2013-01-23 |
이뮤노젠 아이엔씨 |
Cd20 항체 및 이의 용도
|
US9556249B2
(en)
|
2010-02-18 |
2017-01-31 |
Genentech, Inc. |
Neuregulin antagonists and use thereof in treating cancer
|
US20110207789A1
(en)
|
2010-02-19 |
2011-08-25 |
Ye Fang |
Methods related to casein kinase ii (ck2) inhibitors and the use of purinosome-disrupting ck2 inhibitors for anti-cancer therapy agents
|
PE20170779A1
(es)
|
2010-03-04 |
2017-07-04 |
Macrogenics Inc |
Anticuerpos reactivos con b7-h3, fragmentos inmunologicamente activos de los mismos y usos de los mismos
|
US8802091B2
(en)
|
2010-03-04 |
2014-08-12 |
Macrogenics, Inc. |
Antibodies reactive with B7-H3 and uses thereof
|
US20150231215A1
(en)
|
2012-06-22 |
2015-08-20 |
Randolph J. Noelle |
VISTA Antagonist and Methods of Use
|
EP2552947A4
(en)
|
2010-03-26 |
2013-11-13 |
Dartmouth College |
VISTA REGULATORY T CELL MEDIATOR PROTEIN, VISTA BINDING ACTIVE SUBSTANCES AND USE THEREOF
|
US10745467B2
(en)
|
2010-03-26 |
2020-08-18 |
The Trustees Of Dartmouth College |
VISTA-Ig for treatment of autoimmune, allergic and inflammatory disorders
|
WO2011141823A2
(en)
|
2010-05-14 |
2011-11-17 |
Orega Biotech |
Methods of treating and/or preventing cell proliferation disorders with il-17 antagonists
|
WO2011146568A1
(en)
|
2010-05-19 |
2011-11-24 |
Genentech, Inc. |
Predicting response to a her inhibitor
|
EP2575880B1
(en)
|
2010-05-27 |
2019-01-16 |
Genmab A/S |
Monoclonal antibodies against her2 epitope
|
CA3051311A1
(en)
|
2010-05-27 |
2011-12-01 |
Genmab A/S |
Monoclonal antibodies against her2
|
DK2580240T3
(en)
|
2010-06-14 |
2019-03-25 |
Lykera Biomed S A |
S100A4 ANTIBODIES AND THERAPEUTIC APPLICATIONS THEREOF
|
EP2643353A1
(en)
|
2010-11-24 |
2013-10-02 |
Novartis AG |
Multispecific molecules
|
WO2012085111A1
(en)
|
2010-12-23 |
2012-06-28 |
F. Hoffmann-La Roche Ag |
Polypeptide-polynucleotide-complex and its use in targeted effector moiety delivery
|
PL2663579T3
(pl)
|
2011-01-14 |
2017-09-29 |
The Regents Of The University Of California |
Przeciwciała terapeutyczne przeciwko białku receptorowemu ror 1 oraz sposoby ich stosowania
|
EP2500033A1
(en)
*
|
2011-03-17 |
2012-09-19 |
Institut Pasteur |
Method for preparing muliple antigen glycopeptide carbohydrate conjugates
|
US9051619B2
(en)
|
2011-03-25 |
2015-06-09 |
Florida Agricultural and Mechanical University (FAMU) |
Methods and compositions for prostate cancer metastasis
|
TR201905909T4
(tr)
|
2011-04-19 |
2019-05-21 |
Pfizer |
Kanser tedavisi için anti-4-1bb antikorlarının ve adcc indükleyici antikorların kombinasyonları.
|
CA2832389A1
(en)
|
2011-04-20 |
2012-10-26 |
Genmab A/S |
Bispecific antibodies against her2 and cd3
|
US9120858B2
(en)
|
2011-07-22 |
2015-09-01 |
The Research Foundation Of State University Of New York |
Antibodies to the B12-transcobalamin receptor
|
US20140363438A1
(en)
|
2011-08-17 |
2014-12-11 |
Genentech, Inc. |
Neuregulin antibodies and uses thereof
|
EP2768845B1
(en)
*
|
2011-10-19 |
2017-01-18 |
Roche Glycart AG |
Separation method for fucosylated antibodies
|
WO2013063229A1
(en)
|
2011-10-25 |
2013-05-02 |
The Regents Of The University Of Michigan |
Her2 targeting agent treatment in non-her2-amplified cancers having her2 expressing cancer stem cells
|
JP2015500638A
(ja)
|
2011-11-30 |
2015-01-08 |
ジェネンテック, インコーポレイテッド |
癌におけるerbb3変異
|
US9376715B2
(en)
|
2011-12-09 |
2016-06-28 |
Roche Molecular Systems, Inc |
Methods for detecting mutations in the catalytic subunit of the phosphoinositol-3 kinase (PIK3CA) gene
|
CA2855570A1
(en)
|
2011-12-14 |
2013-06-20 |
AbbVie Deutschland GmbH & Co. KG |
Composition and method for the diagnosis and treatment of iron-related disorders
|
EP2791173B1
(en)
|
2011-12-14 |
2020-07-29 |
AbbVie Deutschland GmbH & Co. KG |
Composition and method for the diagnosis and treatment of iron-related disorders
|
CN104144946A
(zh)
|
2011-12-19 |
2014-11-12 |
爱克索马美国有限责任公司 |
治疗痤疮的方法
|
CN107880124B
(zh)
|
2012-01-27 |
2021-08-13 |
艾伯维德国有限责任两合公司 |
用于诊断和治疗与神经突变性相关的疾病的组合物和方法
|
WO2013148315A1
(en)
|
2012-03-27 |
2013-10-03 |
Genentech, Inc. |
Diagnosis and treatments relating to her3 inhibitors
|
WO2013169693A1
(en)
|
2012-05-09 |
2013-11-14 |
Bristol-Myers Squibb Company |
Methods of treating cancer using an il-21 polypeptide and an anti-pd-1 antibody
|
EP2854842A4
(en)
|
2012-05-25 |
2016-11-02 |
Agenus Inc |
IDENTIFICATION OF BREAST CANCER CLASS I MHC PHOSPHOPEPTIDE ANTIGENS USING SHLA TECHNOLOGY AND COMPLEMENTARY ENRICHMENT STRATEGIES
|
US9187735B2
(en)
|
2012-06-01 |
2015-11-17 |
University Of Kansas |
Metal abstraction peptide with superoxide dismutase activity
|
US9890215B2
(en)
|
2012-06-22 |
2018-02-13 |
King's College London |
Vista modulators for diagnosis and treatment of cancer
|
WO2014004549A2
(en)
|
2012-06-27 |
2014-01-03 |
Amgen Inc. |
Anti-mesothelin binding proteins
|
UY34887A
(es)
|
2012-07-02 |
2013-12-31 |
Bristol Myers Squibb Company Una Corporacion Del Estado De Delaware |
Optimización de anticuerpos que se fijan al gen de activación de linfocitos 3 (lag-3) y sus usos
|
US9561266B2
(en)
|
2012-08-31 |
2017-02-07 |
University Of Virginia Patent Foundation |
Target peptides for immunotherapy and diagnostics
|
WO2014039675A2
(en)
|
2012-09-05 |
2014-03-13 |
University Of Virginia Patent Foundation |
Target peptides for colorectal cancer therapy and diagnostics
|
CN109793893B
(zh)
|
2012-09-07 |
2023-05-26 |
达特茅斯大学理事会 |
用于诊断和治疗癌症的vista调节剂
|
TW202206465A
(zh)
*
|
2012-11-14 |
2022-02-16 |
美商再生元醫藥公司 |
重組細胞表面捕捉蛋白質
|
EP2926142B2
(en)
|
2012-11-30 |
2022-07-06 |
F. Hoffmann-La Roche AG |
Identification of patients in need of pd-l1 inhibitor cotherapy
|
US9487587B2
(en)
|
2013-03-05 |
2016-11-08 |
Macrogenics, Inc. |
Bispecific molecules that are immunoreactive with immune effector cells of a companion animal that express an activating receptor and cells that express B7-H3 and uses thereof
|
MX2015012274A
(es)
|
2013-03-14 |
2016-06-02 |
Univ Maryland |
Agentes de sub-regulacion del receptor de androgeno y uso de los mismos.
|
US9308236B2
(en)
|
2013-03-15 |
2016-04-12 |
Bristol-Myers Squibb Company |
Macrocyclic inhibitors of the PD-1/PD-L1 and CD80(B7-1)/PD-L1 protein/protein interactions
|
US9469686B2
(en)
|
2013-03-15 |
2016-10-18 |
Abbott Laboratories |
Anti-GP73 monoclonal antibodies and methods of obtaining the same
|
US10183988B2
(en)
|
2013-06-07 |
2019-01-22 |
Duke University |
Anti-Complement factor H antibodies
|
EP3033088A4
(en)
|
2013-08-12 |
2017-03-08 |
Tokai Pharmaceuticals, Inc. |
Biomarkers for treatment of neoplastic disorders using androgen-targeted therapies
|
WO2015034519A1
(en)
*
|
2013-09-03 |
2015-03-12 |
University Of Virginia Patent Foundation |
Target peptides for immunotherapy and diagnostics
|
US8986691B1
(en)
|
2014-07-15 |
2015-03-24 |
Kymab Limited |
Method of treating atopic dermatitis or asthma using antibody to IL4RA
|
US8980273B1
(en)
|
2014-07-15 |
2015-03-17 |
Kymab Limited |
Method of treating atopic dermatitis or asthma using antibody to IL4RA
|
TWI670283B
(zh)
|
2013-12-23 |
2019-09-01 |
美商建南德克公司 |
抗體及使用方法
|
PL3712174T3
(pl)
|
2013-12-24 |
2022-07-04 |
Janssen Pharmaceutica Nv |
Przeciwciała i fragmenty anty-vista
|
US11014987B2
(en)
|
2013-12-24 |
2021-05-25 |
Janssen Pharmaceutics Nv |
Anti-vista antibodies and fragments, uses thereof, and methods of identifying same
|
US9850225B2
(en)
|
2014-04-14 |
2017-12-26 |
Bristol-Myers Squibb Company |
Compounds useful as immunomodulators
|
WO2015160928A2
(en)
|
2014-04-15 |
2015-10-22 |
University Of Virginia Patent Foundation |
Isolated t cell receptors and methods of use therefor
|
KR102223502B1
(ko)
|
2014-05-09 |
2021-03-05 |
삼성전자주식회사 |
항 c-Met/항 EGFR/항 Her3 다중 특이 항체 및 이의 이용
|
EP3146081B1
(en)
|
2014-05-19 |
2020-10-28 |
The Johns Hopkins University |
Methods for identifying androgen receptor splice variants in subjects having castration resistant prostate cancer
|
DK3151921T3
(da)
|
2014-06-06 |
2019-12-02 |
Bristol Myers Squibb Co |
Antistoffer mod glucocorticoid-induceret tumornekrosefaktor- receptorer (gitr) og anvendelser deraf
|
MX2016016310A
(es)
|
2014-06-11 |
2017-10-20 |
A Green Kathy |
Uso de agonistas y antagonistas vista para suprimir o aumentar la inmunidad humoral.
|
AU2015298263B2
(en)
|
2014-07-31 |
2020-05-14 |
Anji Pharmaceuticals, Inc. |
ApoE mimetic peptides and higher potency to clear plasma cholesterol
|
US11345956B2
(en)
|
2014-08-25 |
2022-05-31 |
The Johns Hopkins University |
Methods and compositions related to prostate cancer therapeutics
|
US9732119B2
(en)
|
2014-10-10 |
2017-08-15 |
Bristol-Myers Squibb Company |
Immunomodulators
|
RU2017119185A
(ru)
|
2014-11-05 |
2018-12-05 |
Дженентек, Инк. |
Антитела против fgfr2/3 и способы их применения
|
US9856292B2
(en)
|
2014-11-14 |
2018-01-02 |
Bristol-Myers Squibb Company |
Immunomodulators
|
SI3221363T1
(sl)
|
2014-11-21 |
2020-09-30 |
Bristol-Myers Squibb Company |
Protitelesa proti CD73 in njihova uporaba
|
MX2017007136A
(es)
|
2014-12-05 |
2017-12-04 |
Immunext Inc |
Identificacion de vsig8 como el receptor vista putativo y su uso para producir moduladores vista/vsig8.
|
US9861680B2
(en)
|
2014-12-18 |
2018-01-09 |
Bristol-Myers Squibb Company |
Immunomodulators
|
US9944678B2
(en)
|
2014-12-19 |
2018-04-17 |
Bristol-Myers Squibb Company |
Immunomodulators
|
TN2017000267A1
(en)
|
2014-12-23 |
2018-10-19 |
Bristol Myers Squibb Co |
Antibodies to tigit
|
CA2972757A1
(en)
|
2014-12-31 |
2016-07-07 |
Arthur M. Krieg |
Combination tumor immunotherapy
|
CN105820251B
(zh)
*
|
2015-01-08 |
2019-10-15 |
江苏康宁杰瑞生物制药有限公司 |
具有共同轻链的双特异性抗体或抗体混合物
|
US20160222060A1
(en)
|
2015-02-04 |
2016-08-04 |
Bristol-Myers Squibb Company |
Immunomodulators
|
HUE049032T2
(hu)
|
2015-02-19 |
2020-08-28 |
Compugen Ltd |
PVRIG elleni antitestek és alkalmazási eljárások
|
US9809625B2
(en)
|
2015-03-18 |
2017-11-07 |
Bristol-Myers Squibb Company |
Immunomodulators
|
HUE061253T2
(hu)
|
2015-05-29 |
2023-06-28 |
Bristol Myers Squibb Co |
Antitestek OX40 ellen és azok felhasználásai
|
EP3313882B1
(en)
|
2015-06-24 |
2020-03-11 |
Janssen Pharmaceutica NV |
Anti-vista antibodies and fragments
|
MX2017016502A
(es)
|
2015-06-29 |
2018-03-12 |
Univ Rockefeller |
Anticuerpos contra cd40 con actividad agonista mejorada.
|
CN108367004B
(zh)
|
2015-09-21 |
2022-09-13 |
阿帕特夫研究和发展有限公司 |
Cd3结合多肽
|
RU2638457C2
(ru)
|
2015-09-28 |
2017-12-13 |
Общество С Ограниченной Ответственностью "Онкомакс" |
Антитела, специфически связывающие рецептор 1 типа фактора роста фибробластов, применение антител для лечения онкологического заболевания, способ получения антител
|
JP2018535655A
(ja)
|
2015-09-29 |
2018-12-06 |
アムジエン・インコーポレーテツド |
Asgr阻害剤
|
US10745382B2
(en)
|
2015-10-15 |
2020-08-18 |
Bristol-Myers Squibb Company |
Compounds useful as immunomodulators
|
EP3371217A1
(en)
|
2015-11-08 |
2018-09-12 |
H. Hoffnabb-La Roche Ag |
Methods of screening for multispecific antibodies
|
WO2017087678A2
(en)
|
2015-11-19 |
2017-05-26 |
Bristol-Myers Squibb Company |
Antibodies against glucocorticoid-induced tumor necrosis factor receptor (gitr) and uses thereof
|
JP6797203B2
(ja)
|
2015-12-17 |
2020-12-09 |
ザ・ジョンズ・ホプキンス・ユニバーシティー |
デスレセプターアゴニストによる全身性硬化症の改善
|
TWI756204B
(zh)
|
2016-02-12 |
2022-03-01 |
比利時商楊森製藥公司 |
抗vista抗體及片段、其用途及鑑定其之方法
|
IL295230A
(en)
|
2016-03-04 |
2022-10-01 |
Bristol Myers Squibb Co |
Combination therapy with anti-cd73 antibodies
|
SG11201807677YA
(en)
|
2016-03-04 |
2018-10-30 |
Univ Rockefeller |
Antibodies to cd40 with enhanced agonist activity
|
US10143746B2
(en)
|
2016-03-04 |
2018-12-04 |
Bristol-Myers Squibb Company |
Immunomodulators
|
EP3432927A4
(en)
|
2016-03-24 |
2019-11-20 |
Gensun Biopharma Inc. |
TRIPLE-SPECIFIC INHIBITORS FOR CANCER TREATMENT
|
US10358463B2
(en)
|
2016-04-05 |
2019-07-23 |
Bristol-Myers Squibb Company |
Immunomodulators
|
WO2017177148A1
(en)
|
2016-04-07 |
2017-10-12 |
The Johns Hopkins University |
Compositions and methods for treating pancreatitis and pain with death receptor agonists
|
CN117562992A
(zh)
|
2016-04-15 |
2024-02-20 |
伊穆奈克斯特股份有限公司 |
抗人vista抗体及其用途
|
CR20180484A
(es)
|
2016-04-15 |
2019-03-05 |
Macrogenics Inc |
Moléculas de unón b7-h3 novedosas, conjugados anticuerpos-fármaco de los mismos y métodos de uso de los mismos
|
CA3021328A1
(en)
|
2016-04-18 |
2017-10-26 |
Celldex Therapeutics, Inc. |
Agonistic antibodies that bind human cd40 and uses thereof
|
US11649284B2
(en)
*
|
2016-04-18 |
2023-05-16 |
Baylor College Of Medicine |
Cancer gene therapy targeting CD47
|
WO2017194554A1
(en)
|
2016-05-10 |
2017-11-16 |
Inserm (Institut National De La Sante Et De La Recherche Medicale) |
Combinations therapies for the treatment of cancer
|
CN109689640B
(zh)
|
2016-07-08 |
2022-01-04 |
百时美施贵宝公司 |
可用作免疫调节剂的化合物
|
EP3484920A2
(en)
|
2016-07-14 |
2019-05-22 |
Bristol-Myers Squibb Company |
Antibodies against tim3 and uses thereof
|
US10144706B2
(en)
|
2016-09-01 |
2018-12-04 |
Bristol-Myers Squibb Company |
Compounds useful as immunomodulators
|
AU2017339858B2
(en)
|
2016-10-03 |
2022-02-17 |
Abbott Laboratories |
Improved methods of assessing GFAP status in patient samples
|
CN109952369B
(zh)
|
2016-10-05 |
2024-03-22 |
弗罗里达中央大学研究基金会 |
涉及nk细胞和抗pdl1癌症治疗的方法和组合物
|
WO2018085750A2
(en)
|
2016-11-07 |
2018-05-11 |
Bristol-Myers Squibb Company |
Immunomodulators
|
KR102599339B1
(ko)
|
2016-12-20 |
2023-11-08 |
브리스톨-마이어스 스큅 컴퍼니 |
면역조정제로서 유용한 화합물
|
US20180230218A1
(en)
|
2017-01-04 |
2018-08-16 |
Immunogen, Inc. |
Met antibodies and immunoconjugates and uses thereof
|
CN109071656B
(zh)
|
2017-01-05 |
2021-05-18 |
璟尚生物制药公司 |
检查点调节物拮抗剂
|
WO2018133873A1
(zh)
|
2017-01-23 |
2018-07-26 |
苏州康宁杰瑞生物科技有限公司 |
Pd-l1结合多肽或化合物
|
WO2018175942A1
(en)
|
2017-03-23 |
2018-09-27 |
Abbott Laboratories |
Methods for aiding in the diagnosis and determination of the extent of traumatic brain injury in a human subject using the early biomarker ubiquitin carboxy-terminal hydrolase l1
|
KR20190133714A
(ko)
|
2017-03-27 |
2019-12-03 |
브리스톨-마이어스 스큅 컴퍼니 |
면역조정제로서 유용한 치환된 이소퀴놀린 유도체
|
TWI788340B
(zh)
|
2017-04-07 |
2023-01-01 |
美商必治妥美雅史谷比公司 |
抗icos促效劑抗體及其用途
|
EP3610268A1
(en)
|
2017-04-15 |
2020-02-19 |
Abbott Laboratories |
Methods for aiding in the hyperacute diagnosis and determination of traumatic brain injury in a human subject using early biomarkers
|
US20230140818A1
(en)
|
2017-04-27 |
2023-05-04 |
The University Of Hong Kong |
Use of hcn inhibitors for treatment of cancer
|
BR112019022476A2
(pt)
|
2017-04-28 |
2020-05-12 |
Abbott Laboratories |
Métodos para o auxílio no diagnóstico e determinação hiperagudos de lesão cerebral traumática usando biomarcadores iniciais em pelo menos duas amostras a partir do mesmo ser humano
|
US10865238B1
(en)
|
2017-05-05 |
2020-12-15 |
Duke University |
Complement factor H antibodies
|
AU2018272054A1
(en)
|
2017-05-25 |
2019-09-26 |
Abbott Laboratories |
Methods for aiding in the determination of whether to perform imaging on a human subject who has sustained or may have sustained an injury to the head using early biomarkers
|
WO2018222784A1
(en)
|
2017-05-30 |
2018-12-06 |
Abbott Laboratories |
Methods for aiding in diagnosing and evaluating a mild traumatic brain injury in a human subject using cardiac troponin i
|
JP7206222B2
(ja)
|
2017-06-23 |
2023-01-17 |
ブリストル-マイヤーズ スクイブ カンパニー |
Pd-1のアンタゴニストとして作用する免疫調節剤
|
JP7454945B2
(ja)
|
2017-07-03 |
2024-03-25 |
アボット・ラボラトリーズ |
血液中のユビキチンカルボキシ末端ヒドロラーゼl1レベルを測定するための、改善された方法
|
WO2019055618A1
(en)
|
2017-09-15 |
2019-03-21 |
Arizona Board Of Regents On Behalf Of Arizona State University |
METHODS OF CLASSIFYING RESPONSES TO ANTICANCER IMMUNOTHERAPY
|
KR20200058506A
(ko)
|
2017-10-03 |
2020-05-27 |
브리스톨-마이어스 스큅 컴퍼니 |
면역조정제
|
EP3704159A1
(en)
|
2017-11-01 |
2020-09-09 |
Bristol-Myers Squibb Company |
Immunostimulatory agonistic antibodies for use in treating cancer
|
WO2019112860A1
(en)
|
2017-12-09 |
2019-06-13 |
Abbott Laboratories |
Methods for aiding in diagnosing and evaluating a traumatic brain injury in a human subject using a combination of gfap and uch-l1
|
EP3721233A2
(en)
|
2017-12-09 |
2020-10-14 |
Abbott Laboratories |
Methods for aiding in the diagnosis and evaluation of a subject who has sustained an orthopedic injury and that has or may have sustained an injury to the head, such as mild traumatic brain injury (tbi), using glial fibrillary acidic protein (gfap) and/or ubiquitin carboxy-terminal hydrolase l1 (uch-l1)
|
WO2019133747A1
(en)
|
2017-12-27 |
2019-07-04 |
Bristol-Myers Squibb Company |
Anti-cd40 antibodies and uses thereof
|
WO2019140229A1
(en)
|
2018-01-12 |
2019-07-18 |
Bristol-Myers Squibb Company |
Antibodies against tim3 and uses thereof
|
CN111868061A
(zh)
|
2018-01-23 |
2020-10-30 |
百时美施贵宝公司 |
用作免疫调节剂的2,8-二酰基-2,8-二氮杂螺[5.5]十一烷化合物
|
WO2019169123A1
(en)
|
2018-03-01 |
2019-09-06 |
Bristol-Myers Squibb Company |
Compounds useful as immunomodulators
|
CA3093407A1
(en)
|
2018-03-23 |
2019-09-26 |
Bristol-Myers Squibb Company |
Antibodies against mica and/or micb and uses thereof
|
MX2020009975A
(es)
|
2018-03-28 |
2020-10-12 |
Bristol Myers Squibb Co |
Proteinas de fusion interleucina-2/receptor alfa de interleucina-2 y metodos de uso.
|
CA3096674A1
(en)
|
2018-04-12 |
2019-10-17 |
Bristol-Myers Squibb Company |
Anticancer combination therapy with cd73 antagonist antibody and pd-1/pd-l1 axis antagonist antibody
|
EP3569618A1
(en)
|
2018-05-19 |
2019-11-20 |
Boehringer Ingelheim International GmbH |
Antagonizing cd73 antibody
|
JP2021529762A
(ja)
|
2018-06-29 |
2021-11-04 |
ノース・キャロライナ・ステイト・ユニヴァーシティ |
術後治療用in situ噴霧生体応答性免疫療法ゲル
|
EP3814381A4
(en)
|
2018-06-29 |
2022-08-10 |
Gensun Biopharma Inc. |
TRI-SPECIFIC ANTAGONISTS
|
WO2020014306A1
(en)
|
2018-07-10 |
2020-01-16 |
Immunogen, Inc. |
Met antibodies and immunoconjugates and uses thereof
|
US20200109200A1
(en)
|
2018-10-09 |
2020-04-09 |
Genentech, Inc. |
Methods and systems for determining synapse formation
|
CA3119838A1
(en)
|
2018-11-16 |
2020-05-22 |
Bristol-Myers Squibb Company |
Anti-nkg2a antibodies and uses thereof
|
WO2020115223A1
(en)
|
2018-12-05 |
2020-06-11 |
Katholieke Universiteit Leuven |
S100a4 as a marker of treatment with spironolactone, pioglitazone and metformin
|
CN109929037B
(zh)
|
2019-04-01 |
2023-03-17 |
华博生物医药技术(上海)有限公司 |
针对程序性死亡配体的结合物及其应用
|
JP2022537453A
(ja)
|
2019-06-21 |
2022-08-25 |
バクシネックス インコーポレーティッド |
セマフォリン4d遮断(sema4d)とdc1療法との併用療法
|
JP2022540571A
(ja)
|
2019-06-28 |
2022-09-16 |
ゲンスン バイオファーマ、インコーポレーテッド |
変異したTGFβ1-RII細胞外ドメインおよび免疫グロブリン足場で構成される抗腫瘍アンタゴニスト
|
WO2021067550A1
(en)
|
2019-10-02 |
2021-04-08 |
Arizona Board Of Regents On Behalf Of Arizona State University |
Methods and compositions for identifying neoantigens for use in treating and preventing cancer
|
JP2022552160A
(ja)
|
2019-10-04 |
2022-12-15 |
ブリストル-マイヤーズ スクイブ カンパニー |
免疫調節剤として有用な化合物
|
EP4118118A1
(en)
|
2020-03-09 |
2023-01-18 |
Bristol-Myers Squibb Company |
Antibodies to cd40 with enhanced agonist activity
|
CA3175523A1
(en)
|
2020-04-13 |
2021-10-21 |
Antti Virtanen |
Methods, complexes and kits for detecting or determining an amount of a .beta.-coronavirus antibody in a sample
|
CN115443171A
(zh)
|
2020-05-08 |
2022-12-06 |
诺沃库勒有限责任公司 |
向多能干细胞施加交变电场的组合物和方法
|
WO2021231732A1
(en)
|
2020-05-15 |
2021-11-18 |
Bristol-Myers Squibb Company |
Antibodies to garp
|
KR20230084469A
(ko)
|
2020-08-04 |
2023-06-13 |
애보트 라피드 다이어그노스틱스 인터내셔널 언리미티드 컴퍼니 |
Sars-cov-2를 검출하기 위한 검정법
|
EP4193149A1
(en)
|
2020-08-04 |
2023-06-14 |
Abbott Laboratories |
Improved methods and kits for detecting sars-cov-2 protein in a sample
|
US20220170948A1
(en)
|
2020-12-01 |
2022-06-02 |
Abbott Laboratories |
Use of one or more biomarkers to determine traumatic brain injury (tbi) in a human subject having received a head computerized tomography scan that is negative for a tbi
|
WO2023102384A1
(en)
|
2021-11-30 |
2023-06-08 |
Abbott Laboratories |
Use of one or more biomarkers to determine traumatic brain injury (tbi) in a subject having received a head computerized tomography scan that is negative for a tbi
|
EP4271998A1
(en)
|
2020-12-30 |
2023-11-08 |
Abbott Laboratories |
Methods for determining sars-cov-2 antigen and anti-sars-cov-2 antibody in a sample
|
JP2024514530A
(ja)
|
2021-04-02 |
2024-04-02 |
ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア |
切断型cdcp1に対する抗体およびその使用
|
WO2022235754A1
(en)
|
2021-05-05 |
2022-11-10 |
Bristol-Myers Squibb Company |
Lactone and lactam containing compounds useful as immunomodulators
|
AU2022279156A1
(en)
|
2021-05-18 |
2023-11-02 |
Abbott Laboratories |
Methods of evaluating brain injury in a pediatric subject
|
WO2022261161A1
(en)
|
2021-06-09 |
2022-12-15 |
Bristol-Myers Squibb Company |
Cyclic peptide immunomodulators
|
CA3222291A1
(en)
|
2021-06-14 |
2022-12-22 |
Jaime MARINO |
Methods of diagnosing or aiding in diagnosis of brain injury caused by acoustic energy, electromagnetic energy, an over pressurization wave, and/or blast wind
|
WO2023283523A1
(en)
|
2021-07-06 |
2023-01-12 |
Bristol-Myers Squibb Company |
2,3-dihydrobenzo[b][l,4]dioxin-6-yl containing compounds useful as immunomodulators
|
AU2022339759A1
(en)
|
2021-08-31 |
2024-03-07 |
Abbott Laboratories |
Methods and systems of diagnosing brain injury
|
CA3232176A1
(en)
|
2021-09-30 |
2023-04-06 |
Beth MCQUISTON |
Methods and systems of diagnosing brain injury
|
WO2023089131A1
(en)
|
2021-11-19 |
2023-05-25 |
Lykera Biomed, S.A. |
Treatment and diagnosis of diseases associated to pathogenic fibrosis
|
WO2023114978A1
(en)
|
2021-12-17 |
2023-06-22 |
Abbott Laboratories |
Systems and methods for determining uch-l1, gfap, and other biomarkers in blood samples
|
WO2023129942A1
(en)
|
2021-12-28 |
2023-07-06 |
Abbott Laboratories |
Use of biomarkers to determine sub-acute traumatic brain injury (tbi) in a subject having received a head computerized tomography (ct) scan that is negative for a tbi or no head ct scan
|
WO2023150652A1
(en)
|
2022-02-04 |
2023-08-10 |
Abbott Laboratories |
Lateral flow methods, assays, and devices for detecting the presence or measuring the amount of ubiquitin carboxy-terminal hydrolase l1 and/or glial fibrillary acidic protein in a sample
|
WO2024006876A1
(en)
|
2022-06-29 |
2024-01-04 |
Abbott Laboratories |
Magnetic point-of-care systems and assays for determining gfap in biological samples
|
WO2024059708A1
(en)
|
2022-09-15 |
2024-03-21 |
Abbott Laboratories |
Biomarkers and methods for differentiating between mild and supermild traumatic brain injury
|